Table 2 Efficacy results of bevacizumab trials [28]

Median difference (months)

Hazard Ratio (95 % confidence interval, P value)

Median difference (months)

Hazard Ratio (95 % confidence interval, P value)

AVF2119g trial [63]

Second line (previously treated with anthracycline and taxane)

2000–2002

462

Bevacizumab plus capecitabine versus capecitabine

0.7

0.98 (0.77–1.25, P < 0.86)

0.6

1.05 (0.86–1.30, P < 0.63)

E2100 trial [4, 10]

First line

2001–2004

722

Bevacizumab plus paclitaxel versus paclitaxel

5.5

0.48 (0.39–0.61, P < 0.0001)

1.7

0.87 (0.72–1.05, P = 0.137)

AVADO trial (BO17708) [13, 28]

First line

2006–2007

736

Bevacizumab plus docetaxel versus docetaxel

0.9

0.62 (0.48–0.79, P = 0.0003)

- 1.7

1.00, 0.76–1.32, P = 0.98)

RIBBON-1 (AVF3694g) [14, 28]

First line

2005–2007

622

Bevacizumab plus taxane/anthracycline versus taxane/anthracycline

1.2

0.64 (0.52–0.80, P < 0.0001)

Not reported

1.11 (0.86–1.43, P = 0.44)

2005–2007

615

Bevacizumab plus capecitabine versus capecitabine

2.9

0.69 (0.56–0.84, P =0.0002)

2.9

0.88 (0.69–1.13, P = 0.33)

RIBBON-2 (AVF3693g) [28]

Second line

2006–2008

684

Bevacizumab plus taxanes, capecitabine or gemcitabine versus taxanes, capecitabine or gemcitabine

2.1

0.78 (0.64–0.93, P = 0.0072)

Non significant difference